Literature DB >> 3103510

The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level.

M Petri, M Rheinschmidt, Q Whiting-O'Keefe, D Hellmann, L Corash.   

Abstract

Recent reviews have suggested a higher frequency of the lupus anticoagulant or related antiphospholipid antibodies in patients with systemic lupus erythematosus (21% to 65%) than was found in earlier studies (6% to 18%). In our study of 60 consecutive patients, we found the frequency of the lupus anticoagulant by Russell viper venom time was 6.7% (95% confidence interval, 16.2 to 1.8) and by anticardiolipin antibody assay was 25% (95% Cl, 37.0 to 15.7), compared with 0% (p = not significant) and 2.5% (p = 0.002), respectively, in the normal control population. The Russell viper venom time (p = 0.0001 by t-test) and anticardiolipin antibody levels (p = 0.01) were significantly associated with presumed thrombotic events (stroke, deep venous thrombosis, and digital gangrene). No association with miscarriage or pulmonary hypertension was detected. The Russell viper venom time was more specific than the anticardiolipin antibody level in the prediction of past presumed thrombotic events, miscarriage, or pulmonary hypertension (100% compared with 84%, p = 0.01).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103510     DOI: 10.7326/0003-4819-106-4-524

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  43 in total

Review 1.  The pulmonary physician and critical care. 5. Management of pulmonary embolism.

Authors:  H H Gray; S Firoozan
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

2.  Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.

Authors:  R Cervera; J Font; A López-Soto; F Casals; L Pallarés; A Bové; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

Review 3.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

4.  Superior mesenteric artery thrombosis associated with antiphospholipid syndrome.

Authors:  M E Hamilton
Journal:  West J Med       Date:  1991-08

5.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

6.  False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion.

Authors:  S Cowchock; J Fort; S Munoz; R Norberg; W Maddrey
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

7.  Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset.

Authors:  A Siamopoulou-Mavridou; M N Manoussakis; A K Mavridis; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

8.  Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome.

Authors:  Ayse Cefle; Murat Inanc; Mehmet Sayarlioglu; Sevil Kamali; Ahmet Gul; Lale Ocal; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

Review 9.  Laboratory evaluation of a bleeding patient.

Authors:  R O Wallerstein
Journal:  West J Med       Date:  1989-01

10.  Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients.

Authors:  Roozbeh Jamshid; Serati Ali Reza; Ghaderi Abbas; Afshariani Raha
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.